Beijing Chuite Biotechnology

Beijing Chuite Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of long-acting recombinant protein therapeutics. The company utilizes its proprietary Fc-fusion protein technology platform to create extended-release versions of hormones and cytokines, aiming to significantly reduce dosing frequency for patients. Its lead candidate, CT-01, is a long-acting human growth hormone (rhGH-Fc) designed to treat growth hormone deficiency in children and adults. The pipeline also includes CT-02, a long-acting parathyroid hormone (rhPTH-Fc) for hypoparathyroidism, and other metabolic-focused programs. By focusing on protein engineering, Chuite Biotechnology seeks to address unmet needs in the endocrinology market through improved drug delivery and patient compliance.